3TR – Taxonomy, Treatment, Targets and Remission (Taxonomie, Behandlung, Targets und Remission)

Innovative Medicines Initiative (IMI)

The DRFZ is partner of the largest-ever Innovative Medicine Initiative 2 (IMI2) immunology project to improve disease management of non-responders to therapy across seven immune-mediated diseases called Taxonomy, Treatment, Targets and Remission (3TR): Identification of the Molecular Mechanisms of non-response to Treatments, Relapses and Remission in Autoimmune, Inflammatory, and Allergic Conditions.

About 3TR

3TR brings together 69 partner organizations from 15 European member states including academic and research institutions, small and medium-sized enterprises (SME) and pharmaceutical companies.

The project is supported with a funding of over € 80 million from the Innovative Medicines Initiative 2 (IMI2), a joint undertaking of the European Commission and the European Federation of Pharmaceutical Industries and Associations (EFPIA).

Role of DRFZ  within 3TR

Within WP1 and WP4 of the 3TR project the DRFZ provides its expertise on high-throughput microbiota analysis by high-resolution microbiota cytometry, high-dimensional single cell analysis and immune monitoring as well as the knowledge of the etiopathology of chronic inflammation.